Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Current Assets (2023 - 2025)

Historic Current Assets for Nuvation Bio (NUVB) over the last 3 years, with Q3 2025 value amounting to $577.5 million.

  • Nuvation Bio's Current Assets rose 222.04% to $577.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $577.5 million, marking a year-over-year increase of 222.04%. This contributed to the annual value of $526.3 million for FY2024, which is 1462.91% down from last year.
  • Latest data reveals that Nuvation Bio reported Current Assets of $577.5 million as of Q3 2025, which was up 222.04% from $623.2 million recorded in Q2 2025.
  • Nuvation Bio's Current Assets' 5-year high stood at $652.6 million during Q1 2023, with a 5-year trough of $475.6 million in Q1 2025.
  • Its 3-year average for Current Assets is $590.4 million, with a median of $608.1 million in 2024.
  • The largest annual percentage gain for Nuvation Bio's Current Assets in the last 5 years was 613.72% (2025), contrasted with its biggest fall of 2178.88% (2025).
  • Nuvation Bio's Current Assets (Quarter) stood at $616.4 million in 2023, then fell by 14.63% to $526.3 million in 2024, then rose by 9.74% to $577.5 million in 2025.
  • Its Current Assets was $577.5 million in Q3 2025, compared to $623.2 million in Q2 2025 and $475.6 million in Q1 2025.